리스페리돈(Risperidone)을 투약 중인 정신분열병 환자에서 지프라시돈(Ziprasidone)으로 교체 투약 시 보이는 임상적 및 대사적 이득에 대한 전향적 개방 연구
Clinical&Metabolic Benefits in Patients with Schizophrenia Switched From Risperidone to Ziprasidone：A Prospective, Open-Label Trial
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives：The purpose of this study was to assess clinical effectiveness and metabolic benefits by switching from risperidone to ziprasidone in chronic stable schizophrenic patients. Methods：A total of 19 patients taking risperidone were switched to a 12-week, open label, flexible dose(80- 160mg/day) of ziprasidone. Current psychiatric status was evaluated by Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), and Global Assessment of Functioning(GAF). Drug induced abnormal movements were assessed using various scales. Laboratory tests including lipid profiles, HbA1c, fasting plasma glucose and electrocardiography were carried out. Results：Of the 19 enrolled patients, 14 patients(73.7%) completed the study. Mean daily dose were 6.1±2.0mg for risperidone at the baseline and 123.1±8.1mg for ziprasidone at the end point of the study. Significant improvements were found on PANSS negative subscale scores(p<.05), with trends towards improved positive and psychopathology subscale scores. Among metabolic parameters, mean total cholesterol, triglyceride, and free fatty acid showed significant improvements(all ps<.05). In line with these findings, mean body weight and hip size significantly decreased from baseline(each p<.05). Regarding tolerability, frequency and severity of abnormal movements were not significantly different between two drugs. The ECG results showed no significant change from baseline in the QTc interval. Conclusion：Our findings supported the use of ziprasidone as a good option for the treatment of stable yet partially resolved outpatients with schizophrenia who has been taking risperidone continually, with benefits in efficacy particularly negative symptoms, reduction of body weight as well as hip size, and improvements in metabolic risk factors.
Abstract
Objectives：The purpose of this study was to assess clinical effectiveness and metabolic benefits by switching from risperidone to ziprasidone in chronic stable schizophrenic patients. Methods：A total of 19 patients taking risperidone were switched to a 12-week, open label, flexible dose(80- 160mg/day) of ziprasidone. Current psychiatric status was evaluated by Positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), and Global Assessment of Functioning(GAF). Drug induced abnormal movements were assessed using various scales. Laboratory tests including lipid profiles, HbA1c, fasting plasma glucose and electrocardiography were carried out. Results：Of the 19 enrolled patients, 14 patients(73.7%) completed the study. Mean daily dose were 6.1±2.0mg for risperidone at the baseline and 123.1±8.1mg for ziprasidone at the end point of the study. Significant improvements were found on PANSS negative subscale scores(p<.05), with trends towards improved positive and psychopathology subscale scores. Among metabolic parameters, mean total cholesterol, triglyceride, and free fatty acid showed significant improvements(all ps<.05). In line with these findings, mean body weight and hip size significantly decreased from baseline(each p<.05). Regarding tolerability, frequency and severity of abnormal movements were not significantly different between two drugs. The ECG results showed no significant change from baseline in the QTc interval. Conclusion：Our findings supported the use of ziprasidone as a good option for the treatment of stable yet partially resolved outpatients with schizophrenia who has been taking risperidone continually, with benefits in efficacy particularly negative symptoms, reduction of body weight as well as hip size, and improvements in metabolic risk factors.
참고문헌 (24)
- Nasrallah HA, "Atypical antipsychotics and metabolic dysregulation: Evaluating the risk", benefit equation and improving the standard of care, 2004, pp.24, S7~S14
- McEvoy JP, "Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the clinical antipsychotic trials of intervention effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES Ⅲ", Schizophr Res, 80, pp.19~32 (2005)
- Harris EC, "Excess mortality of mental disorder", Br J Psychiatry, 173, pp.11~53 (1998)
- Fontaine KR, "Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate", Psychiatry Res, 101, pp.277~288 (2001)
- McElroy SL, "Correlates of overweight and obesity in 644 patients with bipolar disorder", J Clin Psychiatry, 63, pp.207~213 (2002)
- Allison DB, "Antipsychotic-induced weight gain: A comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
- Sernyak MJ, "Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia", Am J Psychiatry, 159, pp.561~566 (2002)
- Kato MM, "Antipsychotic medication: Effects on regulation of glucose and lipids", Expert Opin Pharmacother, 2, pp.1571~1582 (2001)
- Daniel DG, "Ziprasidone 80mg", day and 160mg, Neuropsychopharmacology, pp.1999, 20[DOI]
- Simpson GM, "Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder", Am J Psychiatry, 161, pp.1837~1847 (2004)
- Simpson GM, "Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia", Am J Psychiatry, 162, pp.1535~1538 (2005)
- 안용민, "정신분열병 환자에서 12주간 지프라시돈과 리스페리돈 투여에 의한 체중 증가 및 대사성 부작용 비교", 대한정신약물학회지, 18(2), pp.92~102 (2007), 대한정신약물학회
- Kay SR, "The positive and negative syndrome scale(PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
- Rossi A, "Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone", Int Clin Psychopharmacol, 23, pp.216~222 (2008)
- Ballas C, "Ziprasidone: A novel psychotropic with unique properties", Expert Rev Neurother, 4, pp.179~186 (2004)
- Nemeroff CB, "From clinical research to clinical practice: A 4-year review of ziprasidone", CNS Spectr, 10, pp.1~20 (2005)
- Kinon BJ, "Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia", J Clin Psychopharmacol, 26, pp.632~637 (2006)
- Weiden PJ, "Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia", J Clin Psychiatry, 64, pp.580~588 (2003)
- Kudla D, "Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial", Eur Psychiatry, 22, pp.195~202 (2007)
- Newcomer JW, "Metabolic considerations in the use of antipsychotic medications: A review of recent evidence", J Clin Psychiatry, 68(1), pp.20~27 (2007)
- Montes JM, "Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.383~388 (2007)
- Weiden PJ, "Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone", Neuropsychopharmacology, 33, pp.985~994 (2008)
- Casey DE, "Dyslipidemia and atypical antipsychotic drugs", J Clin Psychiatry, 65(18), pp.27~35 (2004)
- Melkersson K, "Adverse metabolic effects associated with atypical antipsychotics: Literature review and clinical implications", Drugs, 64, pp.701~723 (2004)